Dec 22 (Reuters) - AlloVir said on Friday it will discontinue three late-stage studies testing its experimental antiviral cell therapy after an independent safety board said the studies were unlikely to meet their main goals. (Reporting by Mariam Sunny in Bengaluru; Editing by Devika Syamnath)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7754 USD | +3.19% | -5.02% | +14.06% |
May. 13 | AlloVir, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 20 | North American Morning Briefing : Markets on Hold -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.06% | 85.24M | |
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |
- Stock Market
- Equities
- ALVR Stock
- News AlloVir, Inc.
- AlloVir scraps late-stage studies testing antiviral cell therapy